Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications

Jay Grossman, Charles Banov, Peter Boggs, Edwin A. Bronsky, Robert J. Dockhorn, Howard Druce, Steven R. Findlay, John W. Georgitis, Frank C. Hampel, Harold Kaiser, Paul Ratner, David G. Tinkelman, Martin D. Valentine, Paul Roszko, Elena Zegarelli, Chester Wood

Research output: Contribution to journalArticle

Abstract

To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).

Original languageEnglish (US)
Pages (from-to)1123-1127
Number of pages5
JournalThe Journal of Allergy and Clinical Immunology
Volume95
Issue number5 SUPPL.
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Ipratropium
Nasal Sprays
Rhinitis
Nasal Decongestants
Histamine Antagonists
Therapeutics
Treatment Failure
Steroids
Quality of Life
Safety
Population

Keywords

  • chronic
  • efficacy
  • ipratropium
  • nasal spray
  • Nonallergic rhinitis
  • safety

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. / Grossman, Jay; Banov, Charles; Boggs, Peter; Bronsky, Edwin A.; Dockhorn, Robert J.; Druce, Howard; Findlay, Steven R.; Georgitis, John W.; Hampel, Frank C.; Kaiser, Harold; Ratner, Paul; Tinkelman, David G.; Valentine, Martin D.; Roszko, Paul; Zegarelli, Elena; Wood, Chester.

In: The Journal of Allergy and Clinical Immunology, Vol. 95, No. 5 SUPPL., 1995, p. 1123-1127.

Research output: Contribution to journalArticle

Grossman, J, Banov, C, Boggs, P, Bronsky, EA, Dockhorn, RJ, Druce, H, Findlay, SR, Georgitis, JW, Hampel, FC, Kaiser, H, Ratner, P, Tinkelman, DG, Valentine, MD, Roszko, P, Zegarelli, E & Wood, C 1995, 'Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications', The Journal of Allergy and Clinical Immunology, vol. 95, no. 5 SUPPL., pp. 1123-1127. https://doi.org/10.1016/S0091-6749(95)70216-4
Grossman, Jay ; Banov, Charles ; Boggs, Peter ; Bronsky, Edwin A. ; Dockhorn, Robert J. ; Druce, Howard ; Findlay, Steven R. ; Georgitis, John W. ; Hampel, Frank C. ; Kaiser, Harold ; Ratner, Paul ; Tinkelman, David G. ; Valentine, Martin D. ; Roszko, Paul ; Zegarelli, Elena ; Wood, Chester. / Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. In: The Journal of Allergy and Clinical Immunology. 1995 ; Vol. 95, No. 5 SUPPL. pp. 1123-1127.
@article{18d9dbd9dd5f4b5897a363017ebb4626,
title = "Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications",
abstract = "To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03{\%} in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6{\%}) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).",
keywords = "chronic, efficacy, ipratropium, nasal spray, Nonallergic rhinitis, safety",
author = "Jay Grossman and Charles Banov and Peter Boggs and Bronsky, {Edwin A.} and Dockhorn, {Robert J.} and Howard Druce and Findlay, {Steven R.} and Georgitis, {John W.} and Hampel, {Frank C.} and Harold Kaiser and Paul Ratner and Tinkelman, {David G.} and Valentine, {Martin D.} and Paul Roszko and Elena Zegarelli and Chester Wood",
year = "1995",
doi = "10.1016/S0091-6749(95)70216-4",
language = "English (US)",
volume = "95",
pages = "1123--1127",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications

AU - Grossman, Jay

AU - Banov, Charles

AU - Boggs, Peter

AU - Bronsky, Edwin A.

AU - Dockhorn, Robert J.

AU - Druce, Howard

AU - Findlay, Steven R.

AU - Georgitis, John W.

AU - Hampel, Frank C.

AU - Kaiser, Harold

AU - Ratner, Paul

AU - Tinkelman, David G.

AU - Valentine, Martin D.

AU - Roszko, Paul

AU - Zegarelli, Elena

AU - Wood, Chester

PY - 1995

Y1 - 1995

N2 - To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).

AB - To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).

KW - chronic

KW - efficacy

KW - ipratropium

KW - nasal spray

KW - Nonallergic rhinitis

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=0029068884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029068884&partnerID=8YFLogxK

U2 - 10.1016/S0091-6749(95)70216-4

DO - 10.1016/S0091-6749(95)70216-4

M3 - Article

C2 - 7538520

AN - SCOPUS:0029068884

VL - 95

SP - 1123

EP - 1127

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5 SUPPL.

ER -